Wednesday, August 24, 2016

Rodman ups PharmAthene to market outperform

June 4, 2012 by · Leave a Comment 

Rodman & Renshaw has upgraded PharmAthene (AMEX:PIP) to “market outperform,” with a new 12-month price target of $7, from “market perform,” after a Delaware court judge issued a final judgment with “favorable economics” to PharmAthene in its dispute with SIGA Technologies. Shares of PharmAthene closed at $1.56 on Friday.

Last September, the court ruled that SIGA breached its obligation with PharmAthene to negotiate in good faith for the smallpox drug, ST-246, to be used in case of a biological attack. The judge asked both parties to define their interpretation of net profits, which are to be split 50-50. Since SIGA and PharmAthene could not reach common ground, the judge made a decision for them.

Analyst Elemer Piros estimates that PharmAthene could derive more than $150 million in royalties from the initial 1.7 million-treatment course contract that is in place between defense agency BARDA and SIGA. “In our calculation, a further $965 million could be collected, if the government orders an additional 12 million courses,” he added.

SIGA has 30 days to appeal the judgment.

Print Friendly

Comments are closed.

Email Newsletters with Constant Contact